If anyone is curious, one of the Moderna scientists who helped develop their mRNA vaccine had a thread about this when this first made the rounds:<p>Twitter thread: <a href="https://twitter.com/sailorrooscout/status/1358869462414467085?s=21" rel="nofollow">https://twitter.com/sailorrooscout/status/135886946241446708...</a><p>Easier to read version: <a href="https://threadreaderapp.com/thread/1358869469125296135.html" rel="nofollow">https://threadreaderapp.com/thread/1358869469125296135.html</a><p>> Let’s talk about immunity and why it’s important to take certain factors into consideration when we look at these studies and maybe why the most recent one on AstraZeneca’s effectiveness on the B.1.351 is a tad bit bothersome. For starters this beauty wasn’t tweeted initially.<p>> See that last bullet point? The one of T-cell immunity. Yeah, that’s vital. Why? The study failed to discuss this aspect. You cannot disregard T-cells in the same breath you are discussing B-cells, vaccines and their respective induced antibody responses. It’s a package deal.<p>> T-cells help protect against severe disease. Their analysis shows 76 out of 87 TCB sites (87%) are NOT impacted by the mutations seen in B.1.351. What does this mean? It means the T-cell response generated by AstraZeneca’s vaccine should be highly effective against this variant.<p>> How are you going to disregard our actual immune systems and their ability to make antibodies for later?
Which may I remind you are DRIVEN by vaccines. They teach our bodies to make antibodies for later, not just during active infection (memory T-cells anyone). That’s immunity!<p>If I’m not mistaken, this study doesn’t have enough information on severe disease and hospitalisations since there were no cases in either group. I think we still need more information from the looks of it.